After 1 week, 5.7 mg/kg body weight N-15-LU was administered together with breakfast. A venous blood sample was taken after 6 h. Urine and faeces were collected over a period of 48 and 72 h, respectively. The N-15 abundances were measured by isotope ratio mass spectrometry.\n\nResults: The mean renal N-15-excretion differed significantly between the supplementation of FP and no treatment (32.5 versus 46.3%, P = 0.034), FP and LC1 (32.5 versus 51.6%, P = 0.001), and WPS and LC1 (38.5 versus 51.6%, P = 0.048). The mean faecal N-15-excretion amounted to 42.7% (no treatment), 59.7% (FP), 41.8% (WPS) and 44.0% (LC1). In comparison with no treatment, the urinary (NH3)-N-15-enrichment was significantly

decreased at 16 h after FP supplementation.\n\nConclusion: The prebiotic intake of FP and WPS lowered the colonic selleck generation and the renal excretion of toxic (NH3)-N-15, respectively,

when using N-15-LU as a xenobiotic marker. European Journal of Clinical Nutrition (2010) 64, 1215-1221; doi:10.1038/ejcn.2010.120; published online 4 August 2010″
“Ethanopharmacological relevance: Consortium of yeasts sourced from traditionally used Woodfordia fruticosa flowers proved to be beneficial for fermenting Ashvagandharishta. It resulted in faster fermentation, acceptable organoleptic properties and demonstrable hepatoprotective potential in CCl4 induced find more hepatotoxicity. To formulate Ashvagandharishta using consortium of yeasts and to investigate its physiochemical parameters. Standardize the

formulation with the help of standard withaferin-A and withanolide-A and to evaluate its hepatoprotective potential in CCl4 induced hepatotoxicity in the rat model.\n\nMaterial and methods: Ashvagandharishta was prepared using a 5% consortium of yeasts and ascertained its quality through physiochemical and phytochemical investigation. Withaferin-A and withanolide-A was simultaneously estimated by HPLC for standardization. Hepatoprotective potential was evaluated by administering 2.31 and 1.15 ml/kg doses while considering biochemical parameters like serum AST, ALT, ALP and lipid profile. Gene expression study was carried out for the expression P5091 clinical trial of antioxidant and inflammatory genes such as CAT, GPx and proinflammatory gene IL-6. Histopathology of liver was also studied with the help of H&E staining.\n\nResults: Ashvagandharishta was found organolepticaly acceptable with optimized physiochemical parameters. Withaferin-A and withanolide-A in Ashvagandharishta estimated as 0.3711, 0.7426 (%w/v), respectively. In the CCl4 induced hepato-toxicity model, Ashvagandharishta-2.31 ml/kg dose showed significant decrease in elevated hepatic level of AST(p<0.001), ALT(p<0.01) and ALP(p<0.001). Both doses of Ashvagandharishta showed significant reduction of TG, Cholesterol, VLDL and LDL in serum, with corresponding reduction of (p<0.001) serum-HDL. Ashvagandharishta also showed increased serum protein (p<0.05) and albumin (p<0.